COMPOUNDED BIO identical HRT (cBHRT) is not licensed. This is the sort made in a private lab based on your saliva samples. I will leave you links. It's been criticised by all specialist menopause drs as being unsafe.
The main reason is that the progesterone part (you are using it as a cream?) cannot be properly absorbed by the skin and may cause overgrowth of the womb lining.
The only way to use micronised progesterone is either orally or as a pessary - it comes as a capsule.
The NHS las licensed REGULATED Body identical HRT. (rBHRT)
British Menopause Society statement on Compounded HRT
cBHRT formulation types
E1 and E3 function as competitive inhibitors of E2 because they use the same receptor.
Specialist pharmacies/cBHRT prescribers have interpreted this to mean that E2 needs to be ‘balanced’ with its antagonists, E1 and E3, in order to be physiological. Their rationale forms the basis for compounds such as Biest (E2 plus E3 in a 20/80 ratio) and Triest (E1 plus E2 plus E3 in a 10/10/80 ratio). These combinations are usually compounded with some progesterone and testosterone and/or DHEA. Concerns include:
The absence of medical evidence to support the practice of combining E1 and E3 with E2.
Is the dosage of estrogen higher than it needs to be to control symptoms or too low to control symptoms?
Is the dosage of progesterone sufficient to protect the endometrium in the presence of estrogen?
The absence of warnings on the products regarding potential risks and side effects.
In addition to the issues related to purity, potency and safety of cBHRT, many such products deliver progesterone transdermally in cream or gel preparations. The absorption of the latter is variable with fluctuating tissue availability and as a result may not provide sufficient endometrial protection.
Endometrial protection
Endometrial protection and avoidance of breakthrough bleeding may not be as consistent with separately administered oral MP as it is with standard oral continuous combined regimens. However, this may be partly due to lack of compliance due to the requirement for MP to be used separately with estrogen. Vaginal administration may improve endometrial protection through uterine first pass effect.
Key messages
cBHRT products are not recommended by the BMS they are not evidence based for effectiveness and safety and because rBHRT options are available
There is insufficient evidence to justify multiple serum and saliva hormone tests often claimed to precisely individualise cBHRT
Claims for the benefits of cBHRT have been largely extrapolated from studies of conventional rBHRT
rBHRT studies have demonstrated some advantages over other types of HRT, particularly those with androgenic progestogens
Further data from larger studies on major cardiovascular and breast endpoints are required to confirm the potential benefits of rBHRT
The management of women with menopause related problems should be underpinned by the principles and guidelines of the British Menopause Society and wherever possible, regulated products should be prescribed.